TAO Synergies snaps up 54K Bittensor tokens amid $11M boost – Details

ambcryptoОпубліковано о 2025-10-20Востаннє оновлено о 2025-10-21

Key Takeaways

What is TAO Synergies doing amid Bittensor’s price decline? 

TAO Synergies is aggressively accumulating TAO tokens, expanding its holdings to over 54,000.

What is driving continued bearish pressure on TAO’s price? 

Persistent selling by other investors is outweighing accumulation, pushing TAO below key technical levels.


Following a rejection at $460, Bittensor [TAO] has faced intense bearish pressure, reaching a low of $403.  In fact, at the time of writing, Bittensor was trading at $404, marking a 10.42% decline on daily charts. 

Amid this price decline, institutional investors are taking the opportunity to buy the dip. 

TAO Synergies increase Bittensor holdings

Notably, as TAO retraced on its price charts, TAO Synergies shifted to accumulation. On the 20th of October, TAO Synergies (TAOX ), a Bittensor Treasury company, announced that through acquisition and staking, it increased its holdings. 

As such, the company expanded its TAO portfolio to 54,058 TAO tokens, becoming the largest publicly traded holder of Bittensor. 

Following the acquisition, entrepreneur James Altucher noted that, 

“By scaling our TAO holdings to over 54,000 tokens, we’re not only holding a crypto asset, we’re also staking our claim in a network that’s redefining entrepreneurship and innovation.”

Such a massive acquisition during a market downturn indicates a strong long-term commitment to the project. 

TAO Synergies raised $11 million

Notably, the recent token acquisition comes just days after the firm announced it had secured funding through private placement. 

According to the team, a private funding backed by DCG and James Altucher raised $11 million, which is yet to be deployed. 

These funds will be used to purchase TAO tokens and explore other revenue-generating opportunities, thereby accruing more TAO within the Bittensor ecosystem. 

TAO SynergiesTAO Synergies

Source: Marketwatch

Notably, since TAOX shifted to an aggressive accumulation strategy for the AI coin, its value has surged significantly. In fact, over the past month, TAO Synergies is up 59%  with its market cap hitting $31 million. 

Bittensor still faces bearish pressure 

Surprisingly, despite this accumulation, other investors remain bearish and continue to aggressively sell. 

According to CryptoQuant data, sellers have dominated the market for four consecutive days, as evidenced by Spot Taker CVD. 

Bittensor spot taker CVDBittensor spot taker CVD

Source: CryptoQuant

This metric has remained red since the 16th of October, indicating seller dominance. As a result, the altcoin has recorded a negative Buy-Sell Delta over this period. 

Bittensor buy sell volumeBittensor buy sell volume

Source: Coinalyze

On the 21st of October, for example, Bittensor recorded 40,000 in sell volume and 32,600 in buy volume. This resulted in a negative delta of 7,400, indicating strong spot selling pressure.

Mapping TAO’s path to recovery

Although TAO Synergies continues to accumulate Bittensor tokens, this activity has not yet boosted TAO’s price. The reason is clear: many investors are aggressively selling, creating strong downward pressure on the market. 

As a result, TAO’s Relative Strength Index (RSI) fell to 56, at press time, and formed a bearish crossover, signaling growing seller dominance. 

At the same time, the token dropped below its short-term moving average, further confirming bearish momentum.

TAO RSI & MA CrossTAO RSI & MA Cross

Source: TradingView

Therefore, if these market conditions persist, TAO will likely make more losses on its price charts. A drop from here will see Bittensor retrace to $378, with the 21DMA serving as critical support at $367. 

However, if TAO Synergies manages to absorb the selling pressure, TAO will reclaim 9DMA at $416 and eye $460.

Share

Пов'язані матеріали

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

On August 19, J.P. Morgan (JPM) published a research report analyzing Moderna's recent Phase III trial success for its Individualized Neoantigen Therapy (INT), developed in partnership with Merck, in adjuvant melanoma. The trial met its primary endpoint of significantly improved recurrence-free survival and the key secondary endpoint of distant metastasis-free survival. While JPM acknowledged the strong clinical value of these results, particularly the prevention of distant metastasis, the bank stated that this success was widely anticipated, with an 85% prior probability of success, and is already reflected in Moderna's current market valuation. Following the announcement, Moderna's stock rose in pre-market trading. However, JPM maintained its Underweight rating and $40 price target, implying approximately 36% downside from the current price of ~$63. The core rationale is that the success in adjuvant melanoma, a relatively small market in immuno-oncology, is fully priced in. Moderna's future valuation hinges entirely on INT's ability to demonstrate similar efficacy across broader cancer indications. JPM's valuation model incorporates only a modest risk-adjusted value (~$3/share) for the melanoma approval. Approximately $15/share of its target price is attributed to INT's potential in other cancer types. The report identifies upcoming data readouts in non-melanoma cancers (e.g., lung, head & neck, renal) as the critical variable that will determine the platform's ultimate value. Upside risks include better-than-expected data in these new indications, while downside risks involve clinical failures, regulatory delays, or commercial underperformance. In conclusion, JPM views the pre-market stock move as driven by short covering and trading sentiment rather than a fundamental re-rating. The bank remains bearish, arguing that Moderna must now prove INT's efficacy as a platform technology beyond melanoma to justify its current market cap.

marsbit8 хв тому

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

marsbit8 хв тому

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

The article discusses the U.S. Treasury's recent direct intervention to suppress long-term bond yields through buyback operations. While distinct from traditional Yield Curve Control (YCC), this move is interpreted as direct government intervention in its own financing costs. The author emphasizes the short-term tactical nature of this action and contrasts it with the Federal Reserve's upcoming, potentially divergent, policy stance at Jackson Hole. The core issue is framed as a long-term U.S. strategic dilemma: managing high deficit levels. The analysis argues that deficit reduction cannot realistically come from spending cuts or traditional industries, but must rely on achieving higher economic growth driven by technological breakthroughs. Current monetary tightening, while possibly curbing yields and inflation in the short term, is seen as potentially counterproductive to this necessary long-term investment in technology and supply chain resilience. The piece draws historical parallels, placing the current intervention between the 2000-2002 Treasury buybacks (for liquidity) and larger-scale Fed-led "Operation Twist" maneuvers. The effectiveness of the Treasury's action is deemed limited without Federal Reserve cooperation, which would signify a more significant policy shift. Ultimately, the author views such technical, bureaucratic interventions as treating symptoms rather than the underlying disease of the U.S. economy's structural challenges and "K-shaped" divergence. The conclusion suggests that sustained yield suppression by the Fed, combined with specific geopolitical outcomes, could serve as a catalyst for a more profound discussion on broader U.S. and dollar trajectory.

marsbit8 хв тому

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

marsbit8 хв тому

Торгівля

Спот
活动图片